Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

AstraZeneca stories

Nov 15, 2026

FDA rejects Summit Therapeutics and Akeso's ivonescimab for lung cancer

The FDA declined to approve ivonescimab, a bispecific antibody from Summit Therapeutics and Akeso, after the trial missed its key overall survival endpoint in a narrow lung cancer setting. Analysts had largely anticipated the rejection.

Nov 15, 2026·2 sources
00
Nov 13, 2026

FDA approves durvalumab plus enfortumab vedotin for muscle-invasive bladder cancer

The FDA approved AstraZeneca's durvalumab combined with enfortumab vedotin as neoadjuvant treatment followed by adjuvant durvalumab after radical cystectomy for muscle-invasive bladder cancer. The approval adds a new perioperative immunotherapy option for this high-risk cancer.

Nov 13, 2026·2 sources
00

AstraZeneca cuts 600 US sales jobs in respiratory and immunology

AstraZeneca has eliminated approximately 600 positions from its US respiratory and immunology commercial teams as part of a three-year cost-savings initiative.

Nov 13, 2026·2 sources
00
Nov 10, 2026

AstraZeneca acquires vaccine biotech Omniose to bolster pipeline

AstraZeneca acquired early-stage US biotech Omniose, which is developing vaccines against serious bacterial infections, integrating it into its infectious diseases division.

Nov 10, 2026·2 sources
00
Nov 4, 2026

AstraZeneca made $10 billion offer for obesity drugmaker Rhythm Pharmaceuticals

AstraZeneca made a $10 billion takeover offer for Rhythm Pharmaceuticals, which specializes in treatments for metabolic conditions and severe obesity, according to sources familiar with the matter.

Nov 4, 2026·2 sources
00
Oct 25, 2026

AstraZeneca's sone-ve extends overall survival in advanced stomach cancer trial

AstraZeneca's experimental antibody-drug conjugate sone-ve doubled survival time in patients with advanced stomach cancer who had received at least two prior treatments, exceeding analyst expectations in late-stage trial data.

Oct 25, 2026·2 sources
00
Oct 24, 2026

Amgen's Imdelltra combo cuts death risk 58% in small cell lung cancer trial

Amgen's Imdelltra combined with AstraZeneca's Imfinzi reduced the risk of death by 58% compared to Imfinzi alone in patients with extensive-stage small cell lung cancer, adding eight months of life in a late-stage trial presented at ESMO.

Oct 24, 2026·3 sources
00
Oct 20, 2026

AstraZeneca partners with Oracle to use AI in clinical trials

AstraZeneca announced a collaboration with Oracle to use AI and real-world data to identify eligible patients for clinical trials, monitor safety signals, and improve clinical research efficiency. The first program will focus on hypertension care and research in Abu Dhabi.

Oct 20, 2026·2 sources
00
Oct 15, 2026

AstraZeneca partners with insitro on $40 million AI drug discovery deal

AstraZeneca has teamed up with AI biotech company insitro to discover and develop new treatments for difficult-to-treat liver and heart conditions, with the British drugmaker announcing the partnership on Tuesday.

Oct 15, 2026·2 sources
00

AstraZeneca partners with insitro on $1.86 billion AI drug discovery deal

AstraZeneca signed a collaboration with machine learning biotech insitro worth up to $1.86 billion to discover new medicines for liver and heart diseases using AI-driven drug discovery platforms.

Oct 15, 2026·3 sources
00
Oct 6, 2026

AstraZeneca opens $1 billion R&D center in Boston's Kendall Square

AstraZeneca opened an 18-story research and development facility in Cambridge's Kendall Square, representing a $1 billion investment that will expand the pharmaceutical company's Massachusetts workforce by over 50%. The new global strategic R&D center aims to advance next-generation medicines and includes robotic automation for scientific research.

Oct 6, 2026·4 sources
00
Sep 28, 2026

AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug collaboration

AstraZeneca is investing $2 billion in Summit Therapeutics and collaborating on clinical trials testing their cancer treatments together, with AstraZeneca taking an equity stake in the biotech company.

Sep 28, 2026·5 sources
00
Sep 21, 2026

Imlunestrant combination approved for ESR1-mutated breast cancer

Eli Lilly's imlunestrant/abemaciclib combination has received approval for treating ESR1-mutated breast cancer. The key distinction from AstraZeneca's competing camizestrant/anti-CDK 4/6 therapy is the timing of endocrine therapy switching.

Sep 21, 2026·1 source
00
Sep 16, 2026

England approves breast cancer drug Enhertu after UK-US pharma deal

England's NHS will provide AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for aggressive breast cancer after the drug was previously rejected twice. The approval follows an agreement reached with the companies.

Sep 16, 2026·3 sources
00
Sep 11, 2026

AstraZeneca's breast cancer pill fails late-stage trial after receiving FDA approval

AstraZeneca announced that its breast cancer pill failed to meet the primary endpoint of improving progression-free survival in a late-stage clinical trial. The setback came just one week after the treatment received U.S. regulatory approval.

Sep 11, 2026·4 sources
00
Sep 8, 2026

AstraZeneca lung disease drug shows 30% reduction in COPD exacerbations

AstraZeneca announced its experimental drug tozorakimab achieved approximately 30% reductions in moderate and severe COPD exacerbations compared to standard therapy in two late-stage studies presented at the European Respiratory Society Congress.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug significantly reduces flare-ups in late-stage trials

AstraZeneca's experimental drug for chronic obstructive pulmonary disease significantly reduced dangerous flare-ups across a wide range of patients in two late-stage trials, positioning it as a potential blockbuster treatment for the deadly lung condition.

Sep 8, 2026·3 sources
00

AstraZeneca's experimental COPD drug shows strong results in late-stage trials

AstraZeneca released full results from two successful late-stage trials showing its experimental drug significantly reduced dangerous flare-ups in chronic obstructive pulmonary disease patients across a broad patient population, boosting the treatment's blockbuster potential.

Sep 8, 2026·8 sources
00

FDA approves AstraZeneca's camizestrant for breast cancer despite advisory panel rejection

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) for breast cancer treatment, marking a rare divergence from its expert advisory panel's recommendation and opening a new ctDNA-guided treatment paradigm.

Sep 8, 2026·3 sources
00
Sep 7, 2026

FDA approves AstraZeneca's camizestrant for breast cancer despite negative advisory committee vote

The FDA granted accelerated approval to AstraZeneca's oral SERD camizestrant (Etcamah) in combination with CDK4/6 inhibitors for ESR1-mutated breast cancer, overriding a negative advisory committee recommendation.

Sep 7, 2026·2 sources
00
Aug 27, 2026

AstraZeneca and Amgen's Tezspire meets Phase 3 goals in eosinophilic esophagitis

Tezspire succeeded in a Phase 3 trial for eosinophilic esophagitis, potentially becoming the drug's third approved indication and positioning it to compete with Sanofi's Dupixent, currently the only approved biologic for the condition.

Aug 27, 2026·2 sources
00
Aug 17, 2026

AstraZeneca halts late-stage lung cancer trial of volrustomig after interim analysis shows unlikely success

AstraZeneca discontinued a Phase 3 trial combining its experimental bispecific antibody volrustomig with chemotherapy for lung cancer after an interim data review indicated survival goals would likely not be met. This marks another setback for the company's pipeline as it pursues an $80 billion sales target.

Aug 17, 2026·3 sources
00
Aug 4, 2026

Pathos AI Signs Two Major Breast Cancer Drug Licensing Deals Worth Over $2B, Plans $3B Series E

Pathos AI announced two significant licensing agreements for breast cancer treatments: a $2.2 billion deal with China's Alphamab Oncology for bispecific ADC JSKN016 targeting triple-negative breast cancer, and a co-exclusive agreement with AstraZeneca for ERα degrader AZD4241 for ER-positive breast cancer. The company is reportedly planning to raise a Series E round at a $3 billion valuation.

Aug 4, 2026
00
Aug 2, 2026

AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal

AstraZeneca is reportedly in discussions with Bristol Myers Squibb regarding a potential $400 billion merger, which would create one of the largest pharmaceutical companies globally and reshape the cancer treatment industry.

Aug 2, 2026·1 source
00
Jul 27, 2026

AstraZeneca reports mixed late-stage trial results with Ultomiris failure and Claudin 18.2 ADC success

AstraZeneca announced Monday that its rare disease drug Ultomiris failed a late-stage trial for blood vessel complications following stem cell transplants, while a separate trial of its Claudin 18.2-targeting antibody-drug conjugate in stomach cancer succeeded. The Ultomiris setback adds to concerns about the drugmaker's pipeline following a series of setbacks this year.

Jul 27, 2026
00

AstraZeneca's Sonesitatug Vedotin Shows Significant Survival Improvement in Phase III Gastric Cancer Trial

Phase III CLARITY-Gastric01 trial results showed sonesitatug vedotin (Sone-Ve) achieved statistically significant overall survival improvement in CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma patients in second-line and later settings, meeting its dual primary and key secondary endpoints.

Jul 27, 2026·4 sources
00
Jul 23, 2026

European Commission Approves AstraZeneca's Etcamah for ER-Positive Breast Cancer with ESR1 Mutations

The European Commission has approved AstraZeneca's Etcamah (camizestrant) in combination with a CDK4/6 inhibitor for first-line treatment of adults with ER-positive, HER2-negative advanced breast cancer with emergent ESR1 mutations. The approval is based on SERENA-6 Phase III trial results showing a 56% reduction in risk of disease progression or death.

Jul 23, 2026·9 sources
00
Jul 14, 2026

AstraZeneca Acquires Lung Cancer Drug from China's Dizal Pharmaceutical in $1.5 Billion Deal

AstraZeneca will pay Dizal Pharmaceutical $600 million upfront for global rights to a lung cancer drug, with total deal value reaching $1.5 billion including milestone payments. The drug is commercial-ready and adds to AstraZeneca's oncology franchise.

Jul 14, 2026·2 sources
00
Jul 9, 2026

AstraZeneca and Ionis' heart disease drug Wainua fails pivotal trial, shares plunge

AstraZeneca's shares fell as much as 9% after Wainua, a drug developed with Ionis Pharmaceuticals, unexpectedly failed to meet its primary endpoint in a late-stage trial for ATTR-CM heart disease. The failure has raised concerns about the company's trial design and shaken investor confidence.

Jul 9, 2026·4 sources
00
Jul 8, 2026

AstraZeneca and Daiichi Sankyo Near UK Pricing Agreement for Breast Cancer Drug Enhertu

AstraZeneca and Daiichi Sankyo are nearing a pricing agreement with the UK's National Institute for Health and Care Excellence (NICE) for their breast cancer treatment Enhertu, which could provide access to women in England and Wales with HER2-low breast cancer.

Jul 8, 2026·2 sources
00
Jun 8, 2026

AstraZeneca's experimental obesity pill achieves 10.5% weight loss in phase II trial

AstraZeneca announced results from a phase II trial showing its oral GLP-1 therapy reduced body weight by 10.5%, positioning the company to compete with Eli Lilly in the race to develop convenient pill-based obesity treatments. The drug is advancing to late-stage trials.

Jun 8, 2026·2 sources
00
May 16, 2026

AstraZeneca's Imfinzi-Enfortumab Vedotin Combination Shows Historic Survival Gains in Bladder Cancer Trial

AstraZeneca's VOLGA trial confirms that the Imfinzi EV combination significantly improves overall survival for cisplatin-ineligible bladder cancer patients, representing a major advancement in treatment for this difficult-to-treat population.

May 16, 2026·1 source
00
Apr 29, 2026

AstraZeneca Commits $405M to UK Expansion Following US-UK Pharma Deal

AstraZeneca commits $405 million to expand operations in the United Kingdom following a new US-UK pharma agreement, signaling increased investment and strategic alignment across transatlantic drug markets.

Apr 29, 2026·2 sources
00
Apr 16, 2026

FDA Requests Additional Liver Injury Data on Eli Lilly Obesity Pill Foundayo

The FDA has asked Eli Lilly for more data on liver injury linked to its newly approved obesity pill Foundayo.

Apr 16, 2026·1 source
00

Top claims

  • ▪The FDA concluded ivonescimab's progression-free survival benefit alone did not support a favorable benefit-risk profile as Summit Therapeutics' late-stage primary analysis failed to demonstrate a statistically significant overall survival benefit
  • ▪Approved alternative therapies for post-progression lung cancer include Johnson & Johnson's chemotherapy-free combination treatment incorporating Rybrevant
  • ▪Summit Therapeutics acquired development rights for ivonescimab across North America, Europe, and Japan from China-based Akeso in 2022 under an agreement worth up to $5 billion

Topics

Cancer and Cancer TreatmentClinical trialsCancer treatmentCancer & OncologyDrug Policy, Pricing & ApprovalFDA drug approvalClinical trial endpointsCancer treatment breakthroughsCancer immunotherapyOncologyAsthmaPharmaceutical patentsPharmaceutical IndustryCOPDCorporate strategyCorporate restructuringCorporate layoffsMergers & acquisitions (M&A)Antimicrobial resistanceMergers and acquisitionsInfectious diseaseBiotech innovationVaccine developmentBiotechnologyEli LillyRare diseasesNovo NordiskObesity treatmentWeight loss drugsTargeted cancer therapyRandomized controlled trialBusiness & enterprise AIAI for developersLongevity biotech foundersDrug discoveryLab automationPharmaDrug Approval and Clinical TrialsDrug developmentPrecision medicineHealthcare PolicyClinical Trial Design & EvaluationNew drug application (NDA) processClinical evaluationFDA drug approval processRespiratory diseasesBiologic therapiesDigestive diseasesCancer TypesCancer Treatment & TherapiesAI in drug discoveryVenture capital fundingTrial protocol designPublic healthcareWeight managementWeight loss medications & GLP-1 drugsLifestyle, Wellness and NutritionGLP-1 drugsImmunotherapyTrade agreements & blocsCardiovascular trainingSupplement regulationGLP-1 medications

Related entities

RybrevantChinaUnited StatesPembrolizumabDurvalumabCambridgeEscherichia coliSt. LouisOracleAbu DhabiUnited KingdomCambridge